Zahlen und Investorenversammlung am 1.11. - 500 Beiträge pro Seite

[Dotcomer]

Hallo Ilexaner,

wird morgen interessant. Weiß jemand was über die Erwartungen?
Leider kann ich auch nicht so gut Englisch, so daß ich auf die Liveübertragung um 17:00 MEZ verzichten werde.
Wäre schön wenn einer von Euch hier mal posten würde


ILEX Oncology Inc. to Report Third Quarter 2000 Results and Host Investor Call on November 1, 2000

BusinessWire
Tuesday October 31 3:18pm

SAN ANTONIO--(BUSINESS WIRE)--Oct. 31, 2000--ILEX Oncology Inc. (Nasdaq:ILXO) announced today that it will issue a press release reporting its third quarter 2000 financial results on Wednesday, November 1, 2000 prior to the market opening.

In addition, the company will host an investor conference call on Wednesday, November 1, 2000 at 11:00 a.m. EST to review its third quarter results. The public can listen to the call live on the Internet from the company`s Web site at http://www.ilexoncology.com. To listen, go to the Investors section of the Web site approximately 15 minutes early to register, download and install any necessary audio software.

A replay of the call will also be available at the same Web site address, starting approximately two hours after the call and continuing for three days thereafter.

ILEX Oncology Inc. is a drug development company focused predominantly on the accelerated development of drugs for the treatment and prevention of cancer. The company does this in two ways: by advancing a diversified portfolio of anti-cancer drugs through its ILEX Products subsidiary, and, by offering drug development services on a contract basis to pharmaceutical and biotech companies through its ILEX Oncology Services subsidiary. These complementary businesses draw from the company`s core relationships with international oncology experts, strategic alliances providing unparalleled access to patient recruitment for clinical trials, and simultaneous European and U.S. drug development and approval capabilities. Further information about ILEX can be found on the company`s Web site at www.ilexoncology.com.


Contact: ILEX Oncology Inc., San Antonio
Ann Stevens, Investor Relations 210/949-8230


Source: BusinessWire

[Dotcomer]

Nanu, keiner Info´s über die erwarteten Zahlen?
Oder ist das alles uninteressant, da C. am 14.12. geprüft wird?

[Dotcomer]

Also gut. Hier habt ihr die Zahlen. Was auch immer sie bedeuten.


( BW)(TX-ILEX-ONCOLOGY)(ILXO) ILEX Oncology Announces Third Quarter Results; Company Continues to Expand and Advance Its Product Pipeline

Business Editors & Health/Medical Writers

SAN ANTONIO--(BUSINESS WIRE)--Nov. 1, 2000--ILEX(tm) Oncology Inc. (Nasdaq:ILXO) today reported that total revenues for the third quarter of 2000 reached $7.4 million, up 48% over the third quarter of 1999, driven by a strong increase in contract research (CRO) services revenue.
The third quarter 2000 loss decreased to $8.6 million, or a loss of $0.34 per share, compared to the third quarter 1999 loss of $16.2 million, or a loss of $1.00 per share.
"We continue to deliver on our business plan by deploying capital to expand our product pipeline and accelerate our development program," said President and CEO Richard Love. "We are taking our first angiogenesis inhibitor, NM-3, into the clinic and advancing our apoptosis inducer, APOMINE(tm), into Phase II development. Additionally, we are acting quickly to move ILX-651, our newly in-licensed dolastatin compound, into the clinic early next year."
Commenting on the status of CAMPATH(R) (alemtuzumab), the company`s leading drug candidate, Love said, "ILEX and our development partner, Millennium Pharmaceuticals Inc., are continuing to work constructively with the reviewers at both the U.S. Food and Drug Administration and the European Agency for the Evaluation of Medicinal Products toward obtaining approvals in both markets.
"We are actively preparing to present our Biologics License Application for CAMPATH at the upcoming December meeting of the FDA`s Oncologic Drugs Advisory Committee, and I remain optimistic that CAMPATH will be approved in the U.S. by the end of this year."

Recent Operating Highlights

In addition to releasing its third quarter financial results, the company reviewed the following recent highlights of operations:


-- Notification from the FDA that CAMPATH will be reviewed by the Oncologic Drugs Advisory Committee (ODAC) at the panel`s Dec. 14 meeting.
-- Initiation of a Phase II clinical trial in France of APOMINE, an orally active bisphosphonate tetra-ester derivative being co-developed by ILEX and Symphar S.A. of Geneva, Switzerland, in prostate cancer.
-- Initiation of a Phase I clinical trial in France of NM-3, the company`s lead angiogenesis inhibitor.
-- In-license of ILX-651, a novel, orally active anti-cancer compound, from BASF Pharma of Ludwigshafen, Germany. A synthetic pentapeptide analog of dolastatin, ILX-651 has a mechanism of action similar to taxanes (e.g., TAXOL(R) and Taxotere(R)), yet appears to be active against taxane-resistant tumor models. ILEX plans to file an Investigational New Drug application with the FDA by year-end 2000 and launch clinical trials in early 2001. ILEX and BASF are finalizing an agreement giving ILEX an option on a second compound, Elinafide, and discussing additional oncology product opportunities in the BASF R&D pipeline.

Third Quarter 2000 Financial Results

Total revenue for the quarter increased 48% to $7.4 million, compared with $5.0 million in the third quarter of 1999. This includes $6.6 million in revenue from the company`s CRO business, up 69% from $3.9 million in the same period a year ago.
Research and development (R&D) spending totaled $10.8 million, up 177% from $3.9 million in the same period a year ago, due primarily to in-licensing costs of $4.0 million for ILX-651, as well as increased development spending on the company`s product pipeline, particularly for NM-3 and OXYPRIM(tm).
The company`s share of the loss from the CAMPATH joint venture, Millennium & ILEX Partners, L.P., totaled $2.1 million for the third quarter of 2000, up 5% from $2.0 million in the same period a year ago. Losses in the current period are primarily attributable to sales and marketing expenses in anticipation of CAMPATH commercialization.
Net interest income for the third quarter of 2000 increased to $3.5 million, compared to $0.4 million in the same quarter last year.
Net loss for the third quarter of 2000 totaled $8.6 million, or a loss of $0.34 per share, on 24.9 million weighted average shares outstanding. That compares to a net loss of $16.2 million, or a loss of $1.00 a share, on 16.2 million weighted average shares outstanding in the third quarter of 1999.
As of Sept. 30, 2000, ILEX had $206.4 million in cash, cash equivalents, restricted investments and investments in marketable securities.

First Nine Months of 2000 Financial Highlights

Total revenue for the first nine months of 2000 increased 71% to $21.6 million, compared with $12.6 million in the first nine months of 1999. This includes $19.0 million in revenue from the Company`s CRO business, up 100% from $9.5 million a year ago.
R&D spending totaled $23.0 million in the first nine months of 2000, up 102% from $11.4 million in the first nine months of 1999. The increase was attributable to the in-licensing costs for ILX-651 and to an April 2000 license payment of $1 million for APOMINE, as well as to higher levels of development spending on the company`s product pipeline, including NM-3 and the other emerging angiogenesis inhibitors and OXYPRIM, which is in a pivotal study.
The company`s share of the loss from the CAMPATH joint venture totaled $3.5 million for the first nine months of 2000, a decrease of 10% from $3.9 million in the same period of 1999. Losses in the current period are primarily attributable to sales and marketing expenses in anticipation of CAMPATH commercialization, as well as a license fee incurred by the joint venture in June 2000. CAMPATH development costs have been offset in 2000 by milestone payments received from Schering AG, the marketing and distribution partner for CAMPATH.
Total net loss for the first nine months was $16.5 million, or a loss of $0.69 per share, compared to a net loss of $18.3 million, or a loss of $1.31 per share, a year ago, excluding $25.0 million related to in-process R&D expense and special charges.

Business Outlook

The following projections, based on current expectations, are forward-looking statements. Actual results may differ materially. These statements do not include the potential impact of any product in-licensing or other business transactions outside the normal course of business that may be completed after Sept. 30, 2000.

-- The company expects R&D spending for the year 2000 to range
between $31.0 to $33.0 million. In addition, a milestone
payment of 500,000 shares of ILEX common stock is expected to
be made in the fourth quarter of 2000 related to the 1999
acquisition of Convergence Pharmaceuticals Inc. The in-process
R&D expense for the payment will be recorded at the fair
market value of the stock on the date of issuance.

-- Equity in the loss of the CAMPATH joint venture is expected to
be between $5.0 and $7.0 million for the full year 2000.

-- Revenues from the company`s Services business are expected to
total between $24.0 and $26.0 million for the year 2000, with
a projected 2000 operating margin in the range of 14% to 16%.

-- General and administrative expense is expected to be between
$5.0 and $7.0 million for the year 2000.

Third Quarter Conference Call

ILEX management will host a conference call to review the company`s third quarter 2000 results and business outlook for the year 2000 at 11:00 a.m. Eastern Time on Nov. 1, 2000. The call can be accessed live from the Investors section of the ILEX Web site at http://www.ilexoncology.com. A replay of the call will also be available at the same address starting approximately two hours following the call and continuing for three days following the live Webcast.

[Dotcomer]

ILEX ONCOLOGY INC.
CONSOLIDATED CONDENSED BALANCE SHEETS
(In Thousands)

September 30, December 31,
2000 1999
---- ----
(Unaudited)
ASSETS
Cash, cash equivalents,
restricted investments
and marketable securities $ 206,383 $ 89,126
Receivables, net 12,463 8,481
Prepaid expenses and
other current assets 1,246 576
Investment in and advances
to research and development
partnerships (5,996) (2,534)
Property and equipment, net
of accumulated depreciation 6,203 4,705
Other assets 192 --
--------- ---------
TOTAL ASSETS $ 220,491 $ 100,354
========= =========

LIABILITIES AND
STOCKHOLDERS` EQUITY
Current liabilities $ 17,037 $ 10,324
Long-term liabilities 373 369
Minority interest 5,007 5,082
Stockholders` equity 198,074 84,579
--------- ---------
TOTAL LIABILITIES AND
STOCKHOLDERS` EQUITY $ 220,491 $ 100,354
========= =========


ILEX ONCOLOGY INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In Thousands, Except Per Share Amounts) (Unaudited)

Three Months Ended Nine Months Ended
September 30, September 30,
------------- -------------
2000 1999 2000 1999
---- ---- ---- ----

REVENUE:
Product development $ 851 $ 1,078 $ 2,510 $ 3,147
Contract research
services 6,565 3,914 19,049 9,482
-------- -------- -------- --------
Total revenue 7,416 4,992 21,559 12,629
-------- -------- -------- --------

OPERATING EXPENSES:
Research and
development costs 10,820 3,890 22,974 11,387
CRO costs 4,638 3,824 15,379 10,324
General and
administrative 1,821 754 4,125 2,944
In-process research
and development -- 11,124 -- 11,124
Special charges -- -- -- 13,882
-------- -------- -------- --------
Total operating
expenses 17,279 19,592 42,478 49,661
-------- -------- -------- --------

OPERATING LOSS (9,863) (14,600) (20,919) (37,032)
-------- -------- -------- --------

OTHER INCOME (EXPENSE):
Equity in income (losses) of:
Research and
development
partnerships (2,088) (1,964) (3,499) (3,851)
Contract research
affiliate -- -- -- (3,310)
Interest income, net 3,464 375 8,296 915
Minority interest in
loss of consolidated
subsidiary (75) (7) (225) (7)
-------- -------- -------- --------

LOSS BEFORE INCOME TAXES (8,562) (16,196) (16,347) (43,285)

Provision for foreign
income taxes (6) -- 137 --
-------- -------- -------- --------

NET LOSS $ (8,556) $(16,196) $(16,484) $(43,285)
======== ======== ======== ========

BASIC & DILUTED
NET LOSS PER SHARE $ (0.34) $ (1.00) $ (0.69) $ (3.11)
======== ======== ======== ========

WEIGHTED AVERAGE NUMBER
OF SHARES OF COMMON
STOCK OUTSTANDING 24,914 16,168 23,929 13,928






--30--bd/sa*

CONTACT: ILEX Oncology Inc., San Antonio
Ann Stevens, 210/949-8230

KEYWORD: TEXAS FRANCE GERMANY SWITZERLAND INTERNATIONAL EUROPE
INDUSTRY KEYWORD: BIOTECHNOLOGY MEDICAL PHARMACEUTICAL GOVERNMENT
EARNINGS